Phase II Study of Vinorelbine by Oral Route (in a Hard Gelatine Capsule) for Metastatic Breast Cancer Patients
作者:
W. Queißer,
A. Doss,
H.E. Wander,
K. Bremer,
R. Becher,
K. Rieche,
F.M. Delgado,
L. Edler,
期刊:
Onkologie
(Karger Available online 1991)
卷期:
Volume 14,
issue 1
页码: 35-39
ISSN:0378-584X
年代: 1991
DOI:10.1159/000216942
出版商: S. Karger GmbH
关键词: Phase II trial;Vinorelbine;Breast carcinoma;oral treatment
数据来源: Karger
摘要:
17 patients with advanced low-risk breast carcinoma not previously pretreated by cytostatic agents were treated by Vinorelbine (VIN), 5’-Nor-anhydro-vinblastine, a new semisynthetic compound of the vinca alkaloid series. A dose of 130 mg per week was administered in a hard gelatine formulation for at least eight weeks. Out of 15 evaluable patients, no complete or partial remission was observed. However, there were 9 patients (60%) achieving no change and tumor stabilization, respectively, lasting for a median of 3.0 months. Main toxicities were leukopenia (17.7%, WHO grade 3–4), nausea and vomiting (17.7% WHO grade 3–4), and acute diarrhea (70.6% WHO grade 1–4). Thus, further trials with the oral medication used for this study are not reco
点击下载:
PDF
(1952KB)
返 回